Aptinyx Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aptinyx stock.
View analyst ratings for Aptinyx or view top-rated stocks.

Wall Street analysts have given Aptinyx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aptinyx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Aptinyx is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Aptinyx.

Aptinyx Inc. (NASDAQ:APTX) released its quarterly earnings results on Wednesday, May, 12th. The company reported ($0.22) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.01. The business earned $1 million during the quarter. Aptinyx had a negative trailing twelve-month return on equity of 37.99% and a negative net margin of 2,108.05%.
View Aptinyx's earnings history.

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APTX shares have increased by 19.3% and is now trading at $2.90.
View which stocks have been most impacted by COVID-19.

9 analysts have issued 12-month price targets for Aptinyx's shares. Their forecasts range from $8.00 to $15.00. On average, they expect Aptinyx's share price to reach $11.67 in the next twelve months. This suggests a possible upside of 302.3% from the stock's current price.
View analysts' price targets for Aptinyx or view top-rated stocks among Wall Street analysts.

Some companies that are related to Aptinyx include Zomedica (ZOM), Merus (MRUS), ADVANZ PHARMA (CXRXF), Praxis Precision Medicines (PRAX), Verastem (VSTM), Crinetics Pharmaceuticals (CRNX), Karyopharm Therapeutics (KPTI), Affimed (AFMD), Collegium Pharmaceutical (COLL), Silence Therapeutics (SLN), Sesen Bio (SESN), IDEAYA Biosciences (IDYA), Xenon Pharmaceuticals (XENE), Pharming Group (PHAR) and ORIC Pharmaceuticals (ORIC).
View all of APTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), (KDMN), Matinas BioPharma (MTNB), Cidara Therapeutics (CDTX), ADMA Biologics (ADMA), DURECT (DRRX) and Catalyst Pharmaceuticals (CPRX).

(APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Aptinyx's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.59%), Millennium Management LLC (2.07%), Renaissance Technologies LLC (1.12%), Geode Capital Management LLC (0.89%), Northern Trust Corp (0.68%) and Assenagon Asset Management S.A. (0.63%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Bain Capital Life Sciences Inv, Norbert G Riedel, Rachel E Sherman and Robert J Hombach.
View institutional ownership trends for Aptinyx.

APTX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Morgan Stanley, Renaissance Technologies LLC, JPMorgan Chase & Co., GSA Capital Partners LLP, Assenagon Asset Management S.A., and Goldman Sachs Group Inc..
View insider buying and selling activity for Aptinyx or view top insider-selling stocks.

APTX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Northern Trust Corp, Squarepoint Ops LLC, Nuveen Asset Management LLC, Ameriprise Financial Inc., Barclays PLC, and Dimensional Fund Advisors LP. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Bain Capital Life Sciences Inv, Norbert G Riedel, Rachel E Sherman, and Robert J Hombach.
View insider buying and selling activity for Aptinyx or or view top insider-buying stocks.

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APTX stock can currently be purchased for approximately $2.90.

Aptinyx has a market capitalization of $197.70 million and generates $1.56 million in revenue each year. The company earns $-50,050,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

Aptinyx employs 34 workers across the globe.

The official website for Aptinyx is www.aptinyx.com.

Aptinyx is headquartered at 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201.

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]